Medable trots its way to unicorn status amid virtual trial craze. Is a public debut next?

As it becomes apparent that decentralized clinical trials will likely be a part of drugmakers’ strategies long after the pandemic is over, a tech developer is galloping its way to unicorn status with a $304 million megaround.

Medable unveiled a hefty Series D round on Tuesday — its fourth in...

Click to view original post